Concord Biotech Ltd Stock Price Today (NSE: CONCORDBIO)
Fundamental Score
Concord Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Concord Biotech Ltd share price today is ₹1340.00, down 2.53% on NSE/BSE as of 17 June 2026. Concord Biotech Ltd (CONCORDBIO) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.96K (Cr). The 52-week high for CONCORDBIO share price is ₹2110.90 and the 52-week low is ₹987.00. At a P/E ratio of 46.19x, CONCORDBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.27% and a debt-to-equity ratio of 0.00.
Concord Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Concord Biotech Ltd share price chart: 3.94% return over the past month. 52-week high ₹2110.90, 52-week low ₹987.00.
Concord Biotech Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1076.80 | ₹1183.30 | ₹1036.20 | ₹1166.20 | 18.58L (Cr) | |
| ₹1047.80 | ₹1107.00 | ₹1022.20 | ₹1061.30 | 2.85L (Cr) | |
| ₹1108.40 | ₹1123.60 | ₹1040.30 | ₹1051.20 | 3.36L (Cr) | |
| ₹1135.10 | ₹1145.50 | ₹1096.20 | ₹1099.60 | 1.38L (Cr) | |
| ₹1131.00 | ₹1144.00 | ₹1131.00 | ₹1138.80 | 58.23K (Cr) | |
| ₹1176.40 | ₹1180.00 | ₹1130.00 | ₹1131.90 | 1.05L (Cr) | |
| ₹1129.00 | ₹1176.90 | ₹1116.10 | ₹1153.30 | 2.00L (Cr) | |
| ₹1116.50 | ₹1137.90 | ₹1110.10 | ₹1123.30 | 43.44K (Cr) | |
| ₹1141.00 | ₹1165.50 | ₹1106.70 | ₹1116.00 | 1.12L (Cr) | |
| ₹1127.00 | ₹1150.00 | ₹1127.00 | ₹1143.50 | 83.72K (Cr) |
Concord Biotech Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1047.80 | ₹1183.30 | ₹1022.20 | ₹1166.20 | +11.30% | |
| ₹1158.90 | ₹1234.20 | ₹1040.30 | ₹1051.20 | -9.29% | |
| ₹1065.00 | ₹1164.10 | ₹987.00 | ₹1142.00 | +7.23% | |
| ₹1196.00 | ₹1230.00 | ₹990.60 | ₹1018.40 | -14.85% | |
| ₹1142.60 | ₹1385.00 | ₹1068.60 | ₹1220.60 | +6.83% | |
| ₹1345.60 | ₹1455.00 | ₹1155.70 | ₹1175.20 | -12.66% | |
| ₹1417.60 | ₹1445.10 | ₹1314.90 | ₹1345.60 | -5.08% | |
| ₹1443.80 | ₹1513.00 | ₹1383.00 | ₹1417.60 | -1.81% | |
| ₹1647.70 | ₹1667.60 | ₹1425.20 | ₹1443.80 | -12.37% | |
| ₹1664.39 | ₹1730.00 | ₹1523.90 | ₹1647.70 | -1.00% | |
| ₹1758.60 | ₹1790.70 | ₹1479.90 | ₹1671.04 | -4.98% | |
| ₹1848.70 | ₹1980.00 | ₹1721.00 | ₹1767.30 | -4.40% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Concord Biotech is a speculative bet on API growth and acquisition synergies, but valuation is rich, and execution is key.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Concord Biotech completed the acquisition of Celliimmune Biotech Private Limited for on April 2, 2026. The company submitted its quarterly compliance certificate under SEBI regulations for Q4FY26. MarketsMojo upgraded the stock from 'Strong Sell' to 'Sell' on April 6, 2026, citing technical improvements, but highlighted ongoing financial challenges.
CORE STORY (THE REAL GAME)
Concord Biotech is a play on backward integration into fermentation-based APIs, targeting higher margins and reduced reliance on generic formulations. The market is trying to figure out if recent acquisitions will offset margin pressure.
- Recent acquisition of Celliimmune Biotech
- Upgrade from 'Strong Sell' to 'Sell' indicates potential bottoming
- API segment showing strong growth
- Stronger-than-expected Q4FY26 results
- Positive news flow regarding Celliimmune's cancer research
- New order wins in the API segment
- High valuation relative to industry P/E
- Negative results for three consecutive quarters
- Micro-cap: liquidity risk
FII decreased holdings by 1.07%, DII increased holdings by 0.7%.
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand and innovation.
Profit converting to cash - Yes, FCF 5Y: ₹428.88 Cr
Concord Biotech's 3-6 month outlook hinges on its ability to sustain API growth and successfully integrate Celliimmune. Failure to do so will likely result in a significant correction.
Primary Thesis Risk
Failure to integrate Celliimmune and sustain API growth will crush the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Concord Biotech Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Concord Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CONCORDBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (21.27%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (42.73%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (18.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (18.55% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (1342.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹428.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 46.19x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-33.59%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-20.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-26.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Concord Biotech Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Concord Biotech Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Concord Biotech LtdConcord Biotech...Selected✓ CONCORDBIO • 543960 | 56.3/100 | ₹1340.00₹1340 | ₹14962.48₹14962.48 | 46.19Average 46.2 Average | 21.27%Excellent 21.27% Excellent | 28.25%Excellent 28.25% Excellent | 0.00Excellent 0.0 Excellent | 18.55%Excellent 18.55% Excellent | 18.56%Excellent 18.56% Excellent | 0.75% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Concord Biotech Ltd PE Ratio History
Historical price-to-earnings ratio for CONCORDBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹35.52 | ₹1345.60 | 37.9x |
| FY 2024 | ₹29.45 | ₹2210.75 | 75.1x |
| FY 2023 | ₹22.95 | ₹1471.80 | 64.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Concord Biotech Ltd Dividend History
Annual cash dividends paid by CONCORDBIO — dividend yield 0.75%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹91.54 Cr |
| FY 2024 | ₹71.45 Cr |
| FY 2023 | ₹53.56 Cr |
| FY 2022 | ₹70.52 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Concord Biotech Ltd Quarterly Performance
Latest quarterly metrics for CONCORDBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-20.35%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-33.59%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
18.56%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.55%
Compounded annual net profit growth over 5 years
Concord Biotech Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CONCORDBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Concord Biotech Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Concord Biotech Ltd (CONCORDBIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Concord Biotech Ltd
About CONCORDBIO (Concord Biotech Ltd)
Concord Biotech Ltd is a pioneering force in the realm of biopharmaceutical innovation, dedicated to pushing the boundaries of drug development and manufacturing. At its core, the ...company is driven by a relentless pursuit of scientific excellence, meticulously crafting novel pharmaceutical solutions for a diverse range of global healthcare needs. With a steadfast commitment to research and development, Concord Biotech navigates the complexities of modern medicine, striving to deliver life-enhancing therapies that address critical medical challenges. Their unwavering dedication to quality and innovation positions them as a key player in the pharmaceutical landscape, constantly evolving to meet the ever-changing demands of the industry. Concord Biotech's expertise shines through in its specialized focus on fermentation-derived active pharmaceutical ingredients (APIs), particularly within the crucial therapeutic areas of immunosuppression, oncology, and infection control. By harnessing the power of microbial fermentation, the company meticulously cultivates and refines potent APIs, serving as the building blocks for transformative medications. Concord Biotech's deep understanding of fermentation processes allows it to develop and manufacture APIs with high precision and efficacy, ultimately impacting the lives of patients worldwide. This specialized focus, combined with rigorous quality control measures, solidifies Concord Biotech's reputation as a trusted provider of vital pharmaceutical components. Among its notable offerings, Concord Biotech boasts a portfolio of critical immunosuppressant APIs, playing a vital role in transplant medicine and the management of autoimmune disorders. These APIs, including tacrolimus, mycophenolate, cyclosporine, and sirolimus, are essential in preventing organ rejection and suppressing the immune system in various conditions. By ensuring a reliable supply of these crucial components, Concord Biotech actively contributes to the success of life-saving transplant procedures and the improved quality of life for patients battling immune-related diseases. This commitment to providing high-quality immunosuppressant APIs underscores Concord Biotech's dedication to meeting critical healthcare needs on a global scale.
Company Details
Key Leadership
Corporate Events
CONCORDBIO Share Price: Frequently Asked Questions
What is the current share price of Concord Biotech Ltd?
Concord Biotech Ltd (CONCORDBIO) trades at ₹1340.00 on NSE and BSE. Market cap ₹14.96K (Cr). Educational data only.
What is the P/E ratio of Concord Biotech Ltd?
Concord Biotech Ltd has a P/E of 46.19x vs industry average 31.77x.
What is the Bull Run score for Concord Biotech Ltd?
Concord Biotech Ltd has a Bull Run score of 56.3/100 based on 25+ financial parameters.
Does Concord Biotech Ltd pay dividends?
Concord Biotech Ltd has a dividend yield of 0.75%. Past dividends don't guarantee future payments.
What is the ROE of Concord Biotech Ltd?
Concord Biotech Ltd has ROE of 21.27%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Concord Biotech Ltd?
Concord Biotech Ltd has debt-to-equity of 0.00.
Is Concord Biotech Ltd a good investment?
Bull Run gives Concord Biotech Ltd a score of 56.3/100. This is not investment advice — consult a SEBI-registered advisor.